Search | Clinical Trials Finder

Conditions: Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions: PF-07209960; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 3 more

Conditions: Non-small Cell Lung Cancer
Interventions: PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more

Conditions: Non-Small Cell Lung Cancer
Interventions: INC280 single agent, erlotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Detroit, Michigan + 2 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 15
States / cities: Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Glesatinib, Sitravatinib, Mocetinostat, Nivolumab; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 25
States / cities: Yuma, Arizona • Beverly Hills, California • Duarte, California + 21 more

Conditions: Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions: vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more

Conditions: NSCLC, HNSCC
Interventions: eftilagimod alpha, pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: Immutep S.A.S.; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Huston, Texas

Conditions: Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Breast Cancer, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIC Colorectal Cancer, Stage IIIA Breast Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions: Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 3,665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 159
States / cities: Jonesboro, Arkansas • Martinez, California • Augusta, Georgia + 134 more

Conditions: Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
Interventions: IMM-6-415; Drug
Lead sponsor: Immuneering Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more

Conditions: Lung Cancer
Interventions: carboplatin, celecoxib, gemcitabine hydrochloride, zileuton; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 75
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more

Conditions: Non-small Cell Lung Cancer
Interventions: bexmarilimab (FP-1305), Pembrolizumab; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy); Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Tepotinib, Osimertinib; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 49
States / cities: Yuma, Arizona • Fountain Valley, California • Long Beach, California + 43 more

Conditions: Non-small Cell Lung Cancer NSCLC
Interventions: Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more

Conditions: Lung Cancer
Interventions: lomustine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
Interventions: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Nashville, Tennessee • Houston, Texas

Conditions: Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Radiology, Treatment Planning, Stereotactic Body Radiation Therapy, X-Ray Imaging; Procedure · Other · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Squamous Non-Small Cell Lung Cancer
Interventions: Carboplatin, Veliparib, Paclitaxel, Placebo to veliparib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 38
States / cities: Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more

Conditions: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more

Conditions: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Interventions: BGB-B2033, Tislelizumab, Bevacizumab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Goodyear, Arizona • Duarte, California • Zion, Illinois + 4 more

Conditions: Non - Small Cell Lung Cancer NSCLC
Interventions: MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 33
States / cities: Chandler, Arizona • Anaheim, California • Duarte, California + 29 more

Conditions: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions: ASP546C; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 8 more

Conditions: Lung Cancer
Interventions: Carboplatin, erlotinib hydrochloride, Paclitaxel; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Search by objective public record fields.

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer